Get notified when VYGR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure Of Cfo (new) — The Chief Financial Officer resigned to pursue a new opportunity, triggering a leadership transition in the finance function.
Voyager Therapeutics CFO Nathan Jorgensen resigns; COO Robin Swartz to assume finance role
Filed April 21, 2026 · Period ending April 15, 2026 · ~1 min read
Key Changes
-
high
CFO Nathan Jorgensen resigned effective May 8, 2026, to pursue a new opportunity. The company stated his departure was not due to any disagreement with management or the board.
Item 5.02 verify on EDGAR → -
high
Robin Swartz, current COO and Chief Business Officer, will assume principal financial officer and treasurer roles. Swartz previously served as interim principal financial officer in 2024 and has over 10 years of finance experience at Sanofi Genzyme.
Item 5.02 verify on EDGAR → -
medium
Amy Quinlan, VP of Finance since January 2025, appointed principal accounting officer. She brings controller and finance leadership experience from Vor Biopharma and Tetraphase Pharmaceuticals.
Item 5.02 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (CAG 10-K) is open in full — no account needed.
Partner
Trade VYGR commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify